Literature DB >> 29273844

Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.

J Nicholas Brenton1, Teri Schreiner2, Krystle Karoscik3, Meg Richter3, Samantha Ferrante3, Amy Waldman3, Brenda Banwell3.   

Abstract

BACKGROUND: Studies have shown a negative impact on cognition and brain volume in marijuana-using adult multiple sclerosis (MS) patients and healthy adolescents. Given that onset of MS during childhood and adolescence negatively impacts brain growth and the normal maturation of neuronal networks, the addition of marijuana exposure in these youth may be even more harmful.
OBJECTIVE: Determine attitudes toward and prevalence of recreational marijuana use in MS youth.
METHODS: We surveyed 52 consecutive pediatric-onset MS patients from three pediatric MS centers in the United States. Participants answered a structured questionnaire to capture attitudes toward marijuana and personal use habits, if present.
RESULTS: Nearly half reported use of marijuana, with the majority beginning to use in mid-to-late adolescence. The most popular reasons for using marijuana were relaxation (72%), improvement of medical problems (64%), and stress reduction (52%). Over half (64%) of marijuana users perceived it to have negative effects on memory and focus. Cost and access were not barriers to use, despite all respondents being less than age 21.
CONCLUSION: Youth with MS endorse recreational marijuana as safe, and many use marijuana frequently despite appreciating a negative impact on memory. More detailed understanding of the long-term impact of marijuana use in youth with MS is needed.

Entities:  

Keywords:  Adolescent; Cannabis; Marijuana; Multiple sclerosis; Pediatric

Mesh:

Year:  2017        PMID: 29273844     DOI: 10.1007/s00415-017-8715-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence.

Authors:  Karen L Hanson; Jennifer L Winward; Alecia D Schweinsburg; Krista Lisdahl Medina; Sandra A Brown; Susan F Tapert
Journal:  Addict Behav       Date:  2010-06-13       Impact factor: 3.913

2.  Persistent cannabis users show neuropsychological decline from childhood to midlife.

Authors:  Madeline H Meier; Avshalom Caspi; Antony Ambler; HonaLee Harrington; Renate Houts; Richard S E Keefe; Kay McDonald; Aimee Ward; Richie Poulton; Terrie E Moffitt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

Review 3.  Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

Authors:  Kevin P Hill
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

4.  A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

Authors:  A Novotna; J Mares; S Ratcliffe; I Novakova; M Vachova; O Zapletalova; C Gasperini; C Pozzilli; L Cefaro; G Comi; P Rossi; Z Ambler; Z Stelmasiak; A Erdmann; X Montalban; A Klimek; P Davies
Journal:  Eur J Neurol       Date:  2011-03-01       Impact factor: 6.089

5.  Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

Authors:  R B C Kavia; D De Ridder; C S Constantinescu; C G Stott; C J Fowler
Journal:  Mult Scler       Date:  2010-09-09       Impact factor: 6.312

Review 6.  Maturation of white matter in the human brain: a review of magnetic resonance studies.

Authors:  T Paus; D L Collins; A C Evans; G Leonard; B Pike; A Zijdenbos
Journal:  Brain Res Bull       Date:  2001-02       Impact factor: 4.077

7.  Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.

Authors:  Peter Flachenecker; Thomas Henze; Uwe K Zettl
Journal:  Eur Neurol       Date:  2014-02-12       Impact factor: 1.710

8.  Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  C Vaney; M Heinzel-Gutenbrunner; P Jobin; F Tschopp; B Gattlen; U Hagen; M Schnelle; M Reif
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

9.  Impulsivity, attention, memory, and decision-making among adolescent marijuana users.

Authors:  Donald M Dougherty; Charles W Mathias; Michael A Dawes; R Michael Furr; Nora E Charles; Anthony Liguori; Erin E Shannon; Ashley Acheson
Journal:  Psychopharmacology (Berl)       Date:  2012-11-09       Impact factor: 4.530

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  2 in total

Review 1.  Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.

Authors:  Yara Mouhamed; Andrey Vishnyakov; Bessi Qorri; Manpreet Sambi; Sm Signy Frank; Catherine Nowierski; Anmol Lamba; Umrao Bhatti; Myron R Szewczuk
Journal:  Drug Healthc Patient Saf       Date:  2018-06-11

2.  Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review.

Authors:  Alessia Furgiuele; Marco Cosentino; Marco Ferrari; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2021-01-25       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.